2Tortifm M,Lure BL.The biology and trestmont of superficial bladder cancer.J Clin Oncol,1984,2:505.
3Sylvester BJ,van der Meijden AP,Oosterlinck W,et al.Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables:a combined analysis of 2596 patients from seven EOBTC trials.Eur Urol,2006,49:466-477.
4Yumura Y,Takase K,Kato Y,et al.The significance of urine cytology three consecutive days after transurethral resection as a predictor of superficial bladder cancer recurrence.Hinyokika Kiyo,2004,50:171-176.
6Tolley DA,Panmar MK,Griger KM,et al.The effect of intravesicai mitemycin C on recurrence of newly diagnosed superficial bladder cancer:a further report with 7 years of follow up.J Urol,1996,155:1233-1238.
7Steinberg CN,Calabro F.Adjuvant chemotherapy for bladder cancer.Expert Bey Anticancer Ther,2005,5:987-992.
8van der Mcijden AP,Brausi M,Zambon V,et al.Intravesical instillation of epirubicin,bacillus Calmette-Guerin plus isoniazid for intermediate and high risk Ta,T1 papillary carcinoma of the bladder:a European Organization for Research and Treanont of Cancer gonitor-urinary group randomized phase Ⅲ trial.J Urol,2001,166:476-481.
2[22]Sylvester R, van der Meijiden APM, Oosterlinck W, et al. The side effects of bacillus Calmtte-Guerin in the treatment of Ta T1 bladder cancer do not predict its efficiency. Results from an EORTC Genito-Urinary Group phase Ⅲ trial [J]. Eur Urol Suppl, 2002, 2(1), 191 [Abstract 753].
3[23]Saint F, Kurth N, Maille P, et al. Urinary IL-2 assay for monitoring intravesical bacillus Calmette-Guerin response of superficial bladder cancer during induction course and maintenance therapy [J]. Int J Cancer, 2003, 107(3): 434-440.
4[24]Pagliaro LC, Keyhani A, Williams D, et al. Repeated intravesical instillations of an adenoviral vector in patients with locally advanced bladder cancer: a phase I study of p53 gene therapy [J]. J Clin Oncol, 2003, 21(12): 2247-2253.
5[1]Oosterlinck W, Kurth KH, Schroder F, et al. A prospective European Organization for Research and Treatment of Cancer Genitourinary Group randomized trial comparing transurethral resection followed by single intravesical instillation of epirubicin or water in single state Ta, T1 papillary carcinoma of the bladder [J]. J Urol, 1993, 149(4):749-752.
6[2]The effect of intravesical thiotepa on tumour recurrence after endoscopic treatment of newly diagnosed superficial bladder cancer. A further report with long-term follow-up of a Medical Research Council randomized trial. Medical Research Council Working Party on Urological Cancer, Subgroup on Superficial Bladder Cancer [J]. Br J Urol, 1994, 73 (6): 632-638.
7[3]Lamm DL. Long-term results of intravesical therapy for superficial bladder cancer [J]. Urol Clin North Am, 1992, 19(3): 573-580.
8[4]Van der Heijden AG, Witjes JA. Intravesical chemotherapy: An update-new trend and perspectives [J]. EAU Update Series, 2003(1): 71-79.
9[5]Kobayashi M, Sugaya Y, Yuzawa M, et al. Appropriate intravesical retention time of pirarubicin concentration based on its level in tumor tissue, anti-tumor effect and side effect in intravesical instillation therapy for bladder tumor [J]. Gan To Kagaku Ryoho, 1998, 25(11):1771-1774.
10[6]Glashan RW. A randomized controlled study of intravesical alpha-2b-interferon in carcinoma in situ of the bladder [J]. J Urol, 1990, 144(3):658-661.
9Sylvester R J, van derMeijden AP, OosterlinckW, et al . Predicting recurrence and progression in individual patients with stage Ta Ti bladder cancer using EORTC risk tables : a combined analysis of 2596 patients from seven EORTC trials [ J]. Eur Urol, 2006, 49:466 - 477.
10Tortifm M, Lum BL. The biology and treatment of superficial bladder cancer [J]. J Clin Oncol, 1984, 2: 505.
